BUSINESS

• Combination Therapy of Avastin, Tarceva Significantly Prolongs PFS in PII Study: Roche
  June 6, 2014

• Sales of 26 Pharma Companies Up 10.3% Driven by Strong Overseas Sales
  June 5, 2014

• Astellas to Issue Monthly EPPV Reports on Suglat for One Year: Product Manager
  June 5, 2014

• Sysmex Inostics, Merck Serono of Germany to Codevelop CoDx for Erbitux for Treatment of Colon Cancer
  June 5, 2014

• Eisai’s Halaven Extends OS in Metastatic Breast Cancer Patients
  June 4, 2014

• Taiho’s TS-1 Able to Prolong Life for Metastatic, Relapsed Breast Cancer Patients
  June 4, 2014

• Shionogi Establishes Wholly Owned Subsidiary in Singapore as Foothold for Development and Marketing in ASEAN States
  June 4, 2014

• Nexavar Fails to Show Efficacy in Adjuvant Therapy for Liver Cancer: Bayer Yakuhin
  June 4, 2014

• Eisai’s Anticancer Agent Lenvatinib Significantly Extends PFS in PIII Study
  June 3, 2014

• Teijin Ups FY2015 Japan Sales Target for Feburic to 20-Plus Billion Yen
  June 3, 2014

• MTPC to Merge Its Subsidiary Benesis in October
  June 3, 2014

• Astellas Seeks Approval of Cell-Culture Seasonal Flu Vaccine
  June 2, 2014

• FDA Approves Eisai’s Aloxi for Pediatric Indication, Grants Additional Six-Month Exclusivity
  June 2, 2014

• Announcement: 1st Annual Real World Data Japan 2014 - Tokyo Marriott Hotel, July 15-16
  June 2, 2014

• Suglat Secures Top Position in Anterio’s “Mind Share” Ranking in Both GP, HP Markets in April
  June 2, 2014

• Astellas, MSD Report 133 ADRs at EPPV for Suglat between January and April
  June 2, 2014

• Takeda, US Biotech Venture Agree to Develop, Commercialize Autoimmune Disease Treatment
  May 30, 2014

• Europe Approves Takeda’s UC, CD Treatment Entyvio
  May 30, 2014

• Daiichi Sankyo to Tout Quick Cardiac Event Reduction for Efient
  May 30, 2014

• Bayer Seeks New VTE Indication for Xarelto in Japan
  May 30, 2014

ページ

• « 先頭
• ‹ Prev
• …
• 563
• 564
• 565
• 566
• 567
• 568
• 569
• 570
• 571
• …
• Next ›
• 最終 »